21 Impact Labs AG

21 Impact Labs is focused on reimagining impact funding for the 21st century. The company aims to scale communities, talent, and capital globally. Their primary focus is to advance brain longevity and accelerate solutions and cures to Alzheimer’s disease. 21 Impact Labs operates globally. The company leverages crypto economic mechanisms and Web3 technologies in its operations. 21 Impact Labs utilizes crypto economic mechanisms and Web3 technologies to make impact funding more open, transparent, scalable, and democratic. They have a global impact investment collective funded by the daily sale of Non-Fungible Tokens (NFTs). The company targets the Healthcare, Technology, and Finance industries. The company's competitive advantages include the use of crypto economic mechanisms and Web3 technologies to make impact funding more open, transparent, scalable, and democratic. Additionally, they have a global impact investment collective funded by the daily sale of Non-Fungible Tokens (NFTs). 21 Impact Labs values innovation, transparency, and global impact. The company's leadership includes Brian Magierski, who is the CEO & Founder; Keith Greenfield, who is a Co-founder, Biotech board member and executive; and Tom Shipley, who is a Co-founder, Omnichannel brand building expert and entrepreneur.